7,568.00

-6.50

-0.09%

51,945.00

-188.00

-0.36%

28,181.25

+53.75

+0.19%

Russell 2000 Futures

2,814.70

-3.10

-0.11%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,938.60

-31.00

-0.78%

76,826.40

-1,671.27

-2.13%

Crude Oil Dec 26

96.67

+0.21

+0.22%

US Private Equity

10,836.30

-14.33

-0.13%

Toronto - Delayed Quote CAD

Helix BioPharma Corp. (HBP.TO)

1.0200 +0.0300 (+3.03%)

At close: November 2 at 3:59:51 PM EST

Loading Chart for HBP.TO

Chart Range Bar

Interval:

In partnership with ChartIQ

Helix BioPharma Corp. Announces Fiscal 2026 Year-End Results

Helix BioPharma Corp. Announces Fiscal 2026 Year-End Results

Helix BioPharma Strengthens Biotech Leadership and Corporate Governance Through Planned Board Changes

Helix BioPharma Strengthens Biotech Leadership and Corporate Governance Through Planned Board Changes

Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development

Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

Helix Biopharma Corp. Announces Board Composition Changes

Helix Biopharma Corp. Announces Board Composition Changes

Mobilize your Website

View Site in Mobile | Classic

Share by: